Apr. 2 at 7:22 PM
$CLRB 🚀🚀🚀The Warrant Engine (Financial Strength)
Unlike typical dilutive offerings, CLRB’s warrants are milestone-driven catalysts:
Tranche B (
$4.00 Strike): Triggers upon FDA Approval. It essentially guarantees a
$58M cash infusion exactly when the company needs to launch.
Tranche C (
$5.50 Strike): Triggers upon hitting
$10M in quarterly revenue.
The "Bull" Take: Institutional investors aren't just holding shares; they have pre-committed millions of dollars that only unlock when the company succeeds. This creates a massive floor for the stock.
2. Why it’s a "Strong Buy" (The Conviction)
Wall Street analysts maintain a 100% Buy rating with targets up to
$70+.
The Verdict: CLRB is statistically one of the most asymmetric bets in biotech: Minimal downside (near cash value) with multi-bagger upside (
$30–
$70) upon a deal or approval.💪💪💪
